Loading…
Loading grant details…
| Funder | European Commission |
|---|---|
| Recipient Organization | Organisation Europeenne Pour la Recherche Nucleaire |
| Country | Switzerland |
| Start Date | May 01, 2021 |
| End Date | Apr 30, 2025 |
| Duration | 1,460 days |
| Number of Grantees | 23 |
| Roles | Participant; Coordinator |
| Data Source | European Commission |
| Grant ID | 101008571 |
PRISMAP - The European medical isotope programme: Production of high purity isotopes by mass separation proposes to federate a consortium of the key European intense neutron sources, isotope mass separation facilities and high-power accelerators and cyclotrons, with leading biomedical research institutes and hospitals active in the translation of the emerging radionuclides into medical diagnosis and treatment.
PRISMAP will create a single-entry point for a fragmented user community distributed amongst universities, research centres, industry and hospitals, in a similar way as the National Isotope Development Center NIDC supported by the Department of Energy (DOE) has provided radionuclide sources for users in the USA.
PRISMAP brings together a consortium of 23 beneficiaries from 13 countries, one European Research Laboratory and an International Organisation.
It further receives support of leading associations and institutions in the field such as the European Association of Nuclear Medicine (EANM) and the International Atomic Energy Agency (IAEA).
Our main goal is to provide a sustainable source of high purity grade new radionuclides for medicine, involving from the onset upcoming major European infrastructures, to provide a single-entry point for all researchers active in this field including SMEs, global pharma, nuclear centres, hospitals and universities, using standardised access procedures.
The new isotope enrichment and standardisation techniques triggered in PRISMAP will expand our services and provide them to yet unreachable remote European laboratories.
PRISMAP thus strives to create a paradigm shift in the early phase research on radiopharmaceuticals, targeted drugs for cancer one of the major diseases in Europe - theranostics and personalised medicine, shaping the European isotope landmark as a gold standard to accelerate the development of the pharma industry and ultimately of a better healthcare for the improvement of our citizens life.
Institut Max Von Laue - Paul Langevin; Npl Management Limited; Sciprom Sarl; Commissariat A L Energie Atomique Et Aux Energies Alternatives; Narodowe Centrum Badan Jadrowych; Gsi Helmholtzzentrum Fur Schwerionenforschung Gmbh; Centre Hospitalier Universitaire Vaudois; Ist-Id Associacao Do Instituto Superior Tecnico Para A Investigacao E O Desenvolvimento; Studiecentrum Voor Kernenergie / Centre D'Etude de L'Energie Nucleaire; Medizinische Universitat Innsbruck; Organisation Europeenne Pour la Recherche Nucleaire; Universitetet I Oslo; Danmarks Tekniske Universitet; Klinikum Der Technischen Universität München (Tum Klinikum); Paul Scherrer Institut; Latvijas Universitate; Ebg Medaustron Gmbh; Groupement Interet Public Arronax; Grand Accelerateur National D'Ions Lourds; European Spallation Source Eric; Katholieke Universiteit Leuven; Jrc -Joint Research Centre- European Commission; Istituto Nazionale Di Fisica Nucleare
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant